Nabi Biopharma, GSK Close Option, License Agreement For NicVAX
As per the agreement, Nabi will be entitled to receive an upfront payment of $40m and GSK will be granted an option to exclusively in-license NicVAX on a
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
FreeSlate claimed that it provides researchers with increased experimental capacity and faster decision-making via its microscale, high-throughput technology, lab execution and analysis software, and experienced engineers and application